{"id":949362,"date":"2026-04-07T07:34:24","date_gmt":"2026-04-07T11:34:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\/"},"modified":"2026-04-07T07:34:24","modified_gmt":"2026-04-07T11:34:24","slug":"pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\/","title":{"rendered":"Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse\u2122 Cardiac Catheter System for Atrial Fibrillation"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse\u2122 Cardiac Catheter System for Atrial Fibrillation<\/b><\/p>\n<p class=\"bwalignc\"><i>U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study<\/i><\/p>\n<p>HAYWARD, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pulsebiosciences.com%2F&amp;esheet=54482160&amp;newsitemid=20260407611763&amp;lan=en-US&amp;anchor=Pulse+Biosciences%2C+Inc.&amp;index=1&amp;md5=9cdb1e839731ff9d6dc1ec7a1a329456\">Pulse Biosciences, Inc.<\/a> (Nasdaq: PLSE), developer of nPulse\u2122 technology using proprietary nanosecond pulsed field ablation (nsPFA\u2122) energy, today announced enrollment of the first patients in its <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07018596%3Fterm%3DNANOPULSE%2520AF%26viewType%3DCard%26rank%3D1&amp;esheet=54482160&amp;newsitemid=20260407611763&amp;lan=en-US&amp;anchor=NANOPULSE-AF+study&amp;index=2&amp;md5=15bc2f174e358ae8a85b9c6b4af7c7cd\">NANOPULSE-AF study<\/a>, a prospective, multicenter, IDE pivotal clinical investigation currently evaluating the nPulse\u2122 Cardiac Catheter System for treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation (AF).<\/p>\n<p>\nThe first seven patients in this study were treated at St. Bernards Medical Center in Jonesboro, Arkansas, under the leadership of Devi Nair, MD, Principal Investigator of the Arrhythmia Research Group. &#8220;This is a promising technology, and our team is pleased to have enrolled and treated the first patients in this pivotal trial,&#8221; said Dr. Nair. \u201cThe performance of the nPulse System, combined with integrated catheter mapping using the investigational EnSite X software from Abbott, provides a very user-friendly experience and supports an efficient, reproducible and streamlined workflow. This approach may potentially offer important advantages compared with existing technologies. I look forward to continued enrollment and further clinical evaluation of this strategy in atrial fibrillation ablation for the betterment of all involved.\u201d<\/p>\n<p>\n\u201cEnrolling the first patients in this study marks an important milestone for the Company as we build on the encouraging results from our impressive feasibility experience,\u201d said Darrin Uecker, CTO and Board Member. \u201cWith our nanosecond pulsed field ablation technology and the cardiac catheter\u2019s novel design, we are advancing an entirely differentiated approach that we intend to significantly alter AF treatments. We\u2019re thrilled by this strong start to the NANOPULSE-AF study and look forward to its rapid expansion.\u201d<\/p>\n<p>\nThis milestone builds on Pulse Biosciences\u2019 first-in-human feasibility study, which showed 96% procedural success at 12 months and 100% acute success, exceeding expectations in a field where 20-25% recurrence is typical. Outcomes were reproducible across operators and achieved without anti-arrhythmic drugs.<\/p>\n<p>\n\u201cI am excited to initiate our IDE study with Dr. Nair, a leader in the EP ablation space. This marks an important advancing next step in the clinical development of our nanosecond PFA platform,\u201d said David Kenigsberg, MD, FACC, FHRS, Chief Medical Officer of Pulse Biosciences. \u201cBuilding on encouraging first-in-human data demonstrating safety, procedural efficiency, durable pulmonary vein isolation, and ease of use, our catheter is now tightly integrated with the Abbott EnSite X 3D electroanatomical mapping system, enabling accurate catheter visualization, navigation and contact assessment to support optimal PFA delivery. We look forward to rigorously evaluating this technology in this larger, multicenter setting at up to 30 centers in the United States and Europe.\u201d<\/p>\n<p>\nVivek Reddy, MD, Director of Cardiac Arrhythmia Services at the Mount Sinai Fuster Heart Hospital, NY is the Principal Investigator of the NANOPULSE-AF Study. \u201cFrom the initial clinical experience, the nPulse\u2122 system demonstrated meaningful potential in the treatment of atrial fibrillation,\u201d said Dr. Reddy. \u201cThe NANOPULSE\u2011AF pivotal trial represents an important step forward in evaluating this technology and its potential role in improving procedural outcomes for patients with atrial fibrillation.\u201d<\/p>\n<p>\nThe nPulse Cardiac\u2122 Catheter System delivers energy in billionths of a second \u2014 nanoseconds \u2014 compared with conventional, slower microsecond-based systems. This ultra-fast, non-thermal energy is designed to create precise, durable PVI while minimizing impact to surrounding cardiac structures.<\/p>\n<p>\nKey design features of the System include:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nPrecise Lesion Formation: Creates deep, circumferential lesions without stacking applications or rotating the catheter.<\/p>\n<\/li>\n<li>\nEfficient Workflow: Isolates pulmonary veins with minimal applications and ultra-fast delivery (~5 seconds per application).<\/p>\n<\/li>\n<li>\nProcedure Efficiency: Prior feasibility study showed median left atrial dwell time of 21 minutes and total procedure time of approximately 65 minutes.<\/p>\n<\/li>\n<li>\nEnhanced Visualization: Integrated magnetic EP mapping with catheter-embedded sensors compatible with Abbott\u2019s EnSite X system for real-time 3D electroanatomical visualization to provide a stable location reference, constructing anatomical shells, and standardizing electrophysiological maps to guide therapy.<\/p>\n<\/li>\n<\/ul>\n<p><b>About the NANOPULSE-AF Study<\/b><\/p>\n<p>\nThe NANOPULSE-AF Study is a prospective, multicenter, non-randomized IDE pivotal clinical investigation designed to evaluate the safety and effectiveness of the CellFX nsPFA Cardiac Catheter System in patients with drug-resistant, symptomatic, paroxysmal atrial fibrillation. The Study plans to enroll approximately 215 participants across multiple clinical sites, with the first patients treated at St. Bernards Medical Center in Jonesboro, Arkansas, under the leadership of Dr. Nair. Primary endpoints will be assessed at 6 and 12 months post-ablation to measure procedural success and safety outcomes, supporting the broader clinical development of the nPulse\u2122 system.<\/p>\n<p><b>About Pulse Biosciences\u00ae<\/b><\/p>\n<p>\nPulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company\u2019s proprietary nPulse\u2122 technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue as well as initiating regulated cell death. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation.<\/p>\n<p>\nPulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and\/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nAll statements in this press release that are not historical are forward-looking statements, including, among other things, statements concerning early clinical successes and whether they are predictive of the safety and effectiveness of any medical device such as the nPulse\u2122 Cardiac Catheter System, Pulse Biosciences\u2019 expectations, whether stated or implied, about whether the Company\u2019s nsPFA technology will become either a disruptive treatment option or a superior option for treating atrial fibrillation or any other medical condition, statements about its expectations for the NANOPULSE-AF study such as any projections about enrollment, statements relating to the effectiveness of the Company\u2019s nsPFA technology and nPulse System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company\u2019s expected product development efforts, such as advancement of its nPulse\u2122 Cardiac Catheter to treat paroxysmal atrial fibrillation, statements concerning whether any clinical study will show that the Company\u2019s novel nsPFA mechanism of action and catheter design will deliver durable pulmonary vein isolation or fast and precise ablations in cardiac tissue and streamline workflow, statements concerning market opportunities, customer adoption and future use of the nPulse System to address a range of conditions such as atrial fibrillation, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences\u2019 current expectations, estimates, and projections regarding Pulse Biosciences\u2019 business, operations and other similar or related factors. Words such as \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201canticipate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences\u2019 control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences\u2019 filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260407611763r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260407611763\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260407611763\/en\/<\/a><\/span><\/p>\n<p>\nICR Healthcare<br \/>\n<br \/>Maggie Turano, Account Director<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:PulsebioPR@icrhealthcare.com\">PulsebioPR@icrhealthcare.com<\/a><\/p>\n<p><b>Investors:<br \/>\n<\/b><br \/>Pulse Biosciences, Inc.<br \/>\n<br \/>Jon Skinner, CFO<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:IR@pulsebiosciences.com\">IR@pulsebiosciences.com<\/a><\/p>\n<p>\nOr<br \/>\n<\/p>\n<p>\nGilmartin Group<br \/>\n<br \/>Philip Trip Taylor<br \/>\n<br \/>415.937.5406<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:philip@gilmartinir.com\">philip@gilmartinir.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California Europe United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Software Research General Health Data Management Technology Medical Devices Health Technology Clinical Trials Science Cardiology Biotechnology Practice Management Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260407611763\/en\/1279777\/3\/pulse-logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse\u2122 Cardiac Catheter System for Atrial Fibrillation U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study HAYWARD, Calif.&#8211;(BUSINESS WIRE)&#8211;Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse\u2122 technology using proprietary nanosecond pulsed field ablation (nsPFA\u2122) energy, today announced enrollment of the first patients in its NANOPULSE-AF study, a prospective, multicenter, IDE pivotal clinical investigation currently evaluating the nPulse\u2122 Cardiac Catheter System for treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation (AF). The first seven patients in this study were treated at St. Bernards Medical Center in Jonesboro, Arkansas, under the leadership of Devi Nair, MD, Principal Investigator of the Arrhythmia Research Group. &#8220;This is &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse\u2122 Cardiac Catheter System for Atrial Fibrillation&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-949362","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse\u2122 Cardiac Catheter System for Atrial Fibrillation - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse\u2122 Cardiac Catheter System for Atrial Fibrillation - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse\u2122 Cardiac Catheter System for Atrial Fibrillation U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study HAYWARD, Calif.&#8211;(BUSINESS WIRE)&#8211;Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse\u2122 technology using proprietary nanosecond pulsed field ablation (nsPFA\u2122) energy, today announced enrollment of the first patients in its NANOPULSE-AF study, a prospective, multicenter, IDE pivotal clinical investigation currently evaluating the nPulse\u2122 Cardiac Catheter System for treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation (AF). The first seven patients in this study were treated at St. Bernards Medical Center in Jonesboro, Arkansas, under the leadership of Devi Nair, MD, Principal Investigator of the Arrhythmia Research Group. &#8220;This is &hellip; Continue reading &quot;Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse\u2122 Cardiac Catheter System for Atrial Fibrillation&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-07T11:34:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260407611763r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse\u2122 Cardiac Catheter System for Atrial Fibrillation\",\"datePublished\":\"2026-04-07T11:34:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\\\/\"},\"wordCount\":1329,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260407611763r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\\\/\",\"name\":\"Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse\u2122 Cardiac Catheter System for Atrial Fibrillation - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260407611763r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-04-07T11:34:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260407611763r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260407611763r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse\u2122 Cardiac Catheter System for Atrial Fibrillation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse\u2122 Cardiac Catheter System for Atrial Fibrillation - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\/","og_locale":"en_US","og_type":"article","og_title":"Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse\u2122 Cardiac Catheter System for Atrial Fibrillation - Market Newsdesk","og_description":"Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse\u2122 Cardiac Catheter System for Atrial Fibrillation U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study HAYWARD, Calif.&#8211;(BUSINESS WIRE)&#8211;Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse\u2122 technology using proprietary nanosecond pulsed field ablation (nsPFA\u2122) energy, today announced enrollment of the first patients in its NANOPULSE-AF study, a prospective, multicenter, IDE pivotal clinical investigation currently evaluating the nPulse\u2122 Cardiac Catheter System for treating recurrent, drug-resistant, symptomatic paroxysmal atrial fibrillation (AF). The first seven patients in this study were treated at St. Bernards Medical Center in Jonesboro, Arkansas, under the leadership of Devi Nair, MD, Principal Investigator of the Arrhythmia Research Group. &#8220;This is &hellip; Continue reading \"Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse\u2122 Cardiac Catheter System for Atrial Fibrillation\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-07T11:34:24+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260407611763r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse\u2122 Cardiac Catheter System for Atrial Fibrillation","datePublished":"2026-04-07T11:34:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\/"},"wordCount":1329,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260407611763r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\/","name":"Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse\u2122 Cardiac Catheter System for Atrial Fibrillation - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260407611763r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-04-07T11:34:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260407611763r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260407611763r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulse-biosciences-enrolls-first-patients-in-nanopulse-af-ide-pivotal-clinical-study-evaluating-npulse-cardiac-catheter-system-for-atrial-fibrillation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse\u2122 Cardiac Catheter System for Atrial Fibrillation"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=949362"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949362\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=949362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=949362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=949362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}